MedDataX Logo

The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome

NCT ID: NCT00768820

Last Updated: 2024-05-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-05-31

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome

NCT01127503

Velo-cardio-facial Syndrome Psychosis
TERMINATED PHASE2

An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome

NCT05832255

Fragile X Syndrome Behavior Cognitive Dysfunction
SUSPENDED PHASE2

Study of Acamprosate in Fragile x Syndrome

NCT01911455

Fragile X Syndrome
COMPLETED PHASE1

Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome

NCT01282268

Fragile X Syndrome
COMPLETED PHASE3

Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome

NCT00788073

Fragile X Syndrome
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Velocardiofacial Syndrome Williams Syndrome Fragile X Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

methylphenidate, fluoxetin, risperidone

Intervention Type DRUG

first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

methylphenidate, fluoxetin, risperidone

first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* chromosomal deletion proven by FISH examination
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Chaim Sheba Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof. Doron Gothelf

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Schneider Children's Mediac Center of Israel

Petah Tikva, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Doron Gothelf, MD

Role: CONTACT

[email protected]
972-03-5302663

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Doron Gothelf, MD

Role: primary

972-03-5302663

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SCMCI082455CTIL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
NCT01325220 COMPLETED PHASE3
Acamprosate in Youth With Fragile X Syndrome
NCT01300923 COMPLETED PHASE2
The Brain and Neuropsychological Functioning in Adults With Sapropterin Dihydrochloride Treated Phenylketonuria
NCT02297347 COMPLETED
Neurophysiological and Acute Pharmacological Studies in FXS Patients
NCT02998151 COMPLETED EARLY_PHASE1
A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
NCT02217007 WITHDRAWN PHASE2
Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge
NCT05418049 ACTIVE_NOT_RECRUITING PHASE2
Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome
NCT00637221 COMPLETED PHASE1/PHASE2
An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome
NCT01013480 TERMINATED PHASE2
Neuroimaging GABA Physiology in Fragile X Syndrome
NCT04308954 TERMINATED PHASE1
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
NCT07328529 NOT_YET_RECRUITING PHASE2
A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome
NCT03569631 COMPLETED PHASE2
A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome
NCT00420459 COMPLETED PHASE2
Protein Synthesis in the Brain of Patients With Fragile X Syndrome
NCT00362843 COMPLETED
Randomized Controlled Study of Donepezil in Fragile X Syndrome
NCT01120626 COMPLETED PHASE2
ERG/5-HTP in Fragile X Syndrome (FXS)
NCT05030129 COMPLETED PHASE2
Ganaxolone Treatment in Children With Fragile X Syndrome
NCT01725152 COMPLETED PHASE2
Study on Moebius Syndrome and Congenital Facial Weakness Disorders
NCT02055248 COMPLETED
Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome
NCT01357239 COMPLETED PHASE2
Elucidating the Molecular and Biochemical Basis of the Human AhR-mutation Disease
NCT03566745 UNKNOWN
An Open Label Extension Study in Subjects With Fragile X Syndrome
NCT01555333 TERMINATED PHASE3
Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome
NCT01254045 COMPLETED PHASE2
Psychiatric Phenotype Characterization of Individuals With FOXP1 Syndrome
NCT06211673 COMPLETED
FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.
NCT03718923 RECRUITING
A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome
NCT01750957 COMPLETED PHASE2
Trial of Minocycline to Treat Children With Fragile X Syndrome
NCT01053156 COMPLETED NA